Podcasts about phase iii

The Pittsburgh Steelers started Phase III of their Organized Team Activities (OTAs) Tuesday, and while some might overlook these workouts because their in shorts, there is still a lot of value in these workouts. These workouts might not be an indicator of teams which will win more games in 2025, but they certainly aren't meaningless. That's the topic of the Wednesday "Let's Ride" podcast with Jeff Hartman, as well as the Mailbag Segment. This podcast is a part of the Steel Curtain Network, a part of the Fans First Sports Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

Paul Kuharsky of Paul Kuharsky dot com joins the show to talk all things Titans and NFL as they open up Phase III of OTAs.  What storylines are we paying attention to?  How will the backup QB situation play out?  Is there still a place for Treylon Burks on the team?  We take your phones for PK.

The Titans are hitting the field today for Phase III of OTAs.  There is one national pundit who is giving the Titans some love.  What are we looking for at OTAs, and we get Joe's thoughts on the team trying to build leadership this offseason.  We get into some of the latest news and notes from the SEC spring meetings and what that could mean for the CFP.  We finish up the hour with the Rex Rant.

So fühlt sich der finale Countdown also an! Wir haben das Ende erreicht. Zumindest den Anfang vom Ende. Mit In das Licht von Claudia Gray startet die finale Welle der Hohen Republik. Nicht nur namentlich spiegelt das den einstigen Auftakt mit In die Dunkelheit wider, sondern auch inhaltlich wird ein Zirkelschluss gewagt. Dazwischen sind jedoch sehr viele Perspektivwechsel und damit oberflächliche Figurenzeichnungen versteckt, die kaum lange anhalten. Grund genug, dass Ines, Theo und Tobias genau über diesen Roman sprechen und auch identifizieren, warum weniger und dafür besser gezeichnete Figuren dem Roman gutgetan hätten. Zudem geht es um die Frage, was dieser Roman zum Gesamtprojekt so wirklich beiträgt. Außerdem sprechen wir darüber, wieso die Wookiees viel zu wenig Mitspracherecht erhalten und welche Implikationen das leider verursacht. Zeitmarken spoilerfreier Teil 00:00:00 - Begrüßung 00:02:17 - Erwartungen 00:04:20 - Die größte Überraschung 00:05:25 - Die größte Stärke 00:06:30 - Die größte Schwäche 00:07:54 - Einfluss auf die restlichen Werke? 00:10:11 - Rolle des Romans im Gesamtprojekt 00:11:48 - Was sollte man vorher kennen? 00:13:15 - Warum nicht Claudia Grays Stärke? Spoilerteil 00:17:09 - Abschlussfahrt nach Kashyyyk (Die Handlung) 00:21:08 - Extralange Exposition 00:34:28 - Das Point-of-View-Karussell 00:45:38 - Die Wookiees und die Kolonialherren 00:55:27 - Ro(w) down the Stream 01:03:14 - Disney+ präsentiert: Mkampa all along! 01:10:07 - Chilling in the Light 01:19:54 - Zweifel und Zuversicht 01:27:36 - Wer bin ich? 01:32:52 - Die Fünf-Minuten-Trauer 01:39:42 - Mit der Seuche leben lernen? 01:45:22 - Dez hab ich nicht erwartet! 01:47:25 - Fazit 01:53:12 - Ausblick 01:56:05 - Who lives, who dies, wo tells the story? Blick in die Datenbank Zur Werksübersicht von In das Licht, geschrieben von Claudia Gray Der Roman erschien am 1. April 2025 unter Into the Light bei Disney Lucasfilm-Press auf Englisch Am 15. April folgte dann ein englisches Hörbuch, gesprochen von Amber Lee Connors Die deutsche Version von Panini folgt voraussichtlich am 20. Mai 2025 Die Rezensionen Ines hat das Werk nach Release rezensiert und als Hauptproblem zu viel Personal im Roman identifiziert. Für sie fehlt der Fokuspunkt und damit die charakterliche Tiefe. Sie resümiert: "Leider schafft es Claudia Gray auch in ihrer letzten The High Republic-Geschichte nicht, an die Qualität ihrer eigenständigen Romane heranzukommen, da sie sich aufgrund eines riesigen Casts an Figuren verzettelt und dabei keiner Figur genügend Aufmerksamkeit schenkt. Kombiniert mit Pacing-Schwierigkeiten fühlt sich der Roman daher in Teilen gleichzeitig gehetzt und langatmig an. Trotzdem macht es Spaß, die liebgewonnenen Figuren weiter auf ihrem Weg zu begleiten und die magische Welt von Kashyyyk zu entdecken". Tobias rezensiert nach Erscheinen dann die deutsche Version. Einen Ausschnitt aus dieser Rezension könnt ihr bereits hier lesen: "In das Licht spiegelt dem Titel nach den ersten YA-Roman der Hohen Republik – In die Dunkelheit – wider. Das erfüllt er auch inhaltlich und schließt die Klammer damit zufriedenstellend. Wie Claudia Gray das jedoch herleitet und wie sprunghaft sie in ihrer Wahl der Hauptfiguren ist, stört das Gesamtbild. Mit keiner Figur eifern wir so wirklich mit, alle sind Plot-Träger ohne viel emotionale Momente oder gar inneren Monologen. Wenn diese jedoch mal hervorstechen, wird der Wunsch nur größer, mehr darüber zu erfahren. Doch da muss schon der vierte PoV in diesem Kapitel auch noch seinen Senf dazugeben. Am Ende entsteht eine Melange, die zwar das Projekt um einen Etappensieg bereichert, selbst aber nicht zu den Werken gehört, die der Hohen Republik ihre Seele geben". Den JediCast abonnieren Wir sind auf allen gängigen Podcast-Plattformen vertreten! Abonniert uns also gerne auf Spotify, Apple Podcasts, Google Podcasts (etc.), oder fügt bequem unsere Feeds in euren präferierten Podcast-Player ein. Alle Links dazu findet ihr oben unter dem Player verlinkt sowie auch jederzeit unter dem Audioplayer in der rechten Sidebar. Wir freuen uns auch immer über Bewertungen auf den jeweiligen Podcast-Seiten. Falls ihr umfangreichere Anmerkungen habt, schreibt auch gerne eine Mail an podcast@jedi-bibliothek.de! Eure Meinung Was haltet ihr von Claudia Grays finalem YA-Roman der Hohen Republik? Teilt ihr unsere doch eher kritische Meinung oder habt ihr euch voll in den Figuren und der Welt verloren? Wie blickt ihr auf den finalen Erwachsenenroman und welche Wünsche und Ängste habt ihr bezüglich der Luminous Nine? Star Wars: Die Hohe Republik ist ein mehrjähriges Buch- und Comicprogramm, das hunderte Jahre vor den Skywalker-Filmen spielt und die Jedi in ihrer Blütezeit zeigt. Weitere Infos, News, Podcasts und Rezensionen gibt es in unserem Portal und in der Datenbank. Beachtet auch unsere Guides zur Lesereihenfolge von Phase I, Phase II und Phase III.

Faraday Copper says they have made a new blind discovery of the Winchester Breccia during their Phase III drill program at the Copper Creek Project in Arizona. New exploration results from Outcrop Silver & Gold and Soma Gold. Kenorland Minerals has wrapped up its winter drill program with Auranova at the South Uchi Project. This episode of Mining Stock Daily is brought to you by... Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Calibre Mining is a Canadian-listed, Americas focused, growing mid-tier gold producer with a strong pipeline of development and exploration opportunities across Newfoundland & Labrador in Canada, Nevada and Washington in the USA, and Nicaragua. With a strong balance sheet, a proven management team, strong operating cash flow, accretive development projects and district-scale exploration opportunities Calibre will unlock significant value.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.calibremining.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Papilledema describes optic disc swelling (usually bilateral) arising from raised intracranial pressure. Due to its serious nature, there is a fear of underdiagnosis; hence, one major stumbling points is correct identification, which typically requires a thorough ocular examination including visual field testing. In this episode, Kait Nevel, MD speaks with Susan P. Mollan, MBChB, PhD, FRCOphth, author of the article “Papilledema” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Mollan is a professor and neuro-ophthalmology consultant at University Hospitals Birmingham in Birmingham, United Kingdom. Additional Resources Read the article: Papilledema Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Guest: @DrMollan Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kait Nevel. Today I'm interviewing Dr Susan Mollan about her article Papilledema Diagnosis and Management, which appears in the April 2025 Continuum issue on neuro-ophthalmology. Susie, welcome to the podcast, and please introduce yourself to our audience. Dr Mollan: Thank you so much, Kait. It's a pleasure to be here today. I'm Susie Mollan, I'm a consultant neuro-ophthalmologist, and I work at University Hospitals Birmingham- and that's in England. Dr Nevel: Wonderful. So glad to be talking to you today about your article. To start us off, can you please share with us what you think is the most important takeaway from your article for the practicing neurologist? Dr Mollan: I think really the most important thing is about examining the fundus and actually trying to visualize the optic nerves. Because as neurologists, you're really acutely trained in examining the cranial nerves, and often people shy away from looking at the eyes. And it can give people such confidence when they're able to really work out straightaway whether there's going to be a problem or there's not going to be a problem with papilledema. And I guess maybe a little bit later on we can talk about the article and tips and tricks for looking at the fundus. But I think that would be my most important thing to take away. Dr Nevel: I'm so glad that you started with that because, you know, that's something that I find with trainees in general, that they often find one of the more daunting or challenging aspects of learning, really, how to do an excellent neurological exam is examining the fundus and feeling confident in diagnosing papilledema. What kind of advice do you give to trainees learning this skill? Dr Mollan: So, it really is practice and always carrying your ophthalmoscope with you. There's lots of different devices that people can choose to buy. But really, if you have a direct ophthalmoscope, get it out in the ward, get it out in clinic. Look at those patients that you'd know have alternative diagnosis, but it gives you that practice. I also invite everybody to come to the eye clinic because we have dilated patients there all the time. We have diabetic retinopathy clinics, and it makes it really easy to start to acquire those skills because I think it's very tricky, because you're getting a highly magnified view of the optic nerve and you've got to sort out in your head what you're actually looking at. I think it's practice. and then use every opportunity to really look at the fundus, and then ask your ophthalmology colleagues whether you can go to clinic. Dr Nevel: Wonderful advice. What do you think is most challenging about the evaluation of papilledema and why? Dr Mollan: I think there are many different aspects that are challenging, and these patients come from lots of different areas. They can come from the family doctor, they can come from an optician or another specialist. A lot of them can have headache. And, as you know, headache is almost ubiquitous in the population. So, trying to pull out the sort of salient symptoms that can go across so many different conditions. There's nothing that's pathognomonic for papilledema other than looking at the optic nerves. So, I think it's difficult because the presentation can be difficult. The actual history can be challenging. There are those rare patients that don't have headache, don't have pulsatile tinnitus, but can still have papilledema. So, I think it- the most challenging thing is actually confirming papilledema. And if you're not able to confirm it, getting that person to somebody who's able to help and confirm or refute papilledema is the most important thing. Dr Nevel: Yeah, right. Because you talk in your article the importance of distinguishing between papilledema and some other diagnoses that can look like papilledema but aren't papilledema. Can you talk about that a little bit? Dr Mollan: Absolutely. I think in the article it's quite nice because we were able to spend a bit of time on a big table going through all the pseudopapilledema diagnoses. So that includes people with shortsightedness, longsightedness, people with optic nerve head drusen. And we've been very fortunate in ophthalmology that we now have 3D imaging of the optic nerve. So, it makes it quite clear to us, when it's pseudopapilledema, it's almost unfair when you're using the direct ophthalmoscope that you don't get a cross sectional image through that optic nerve. So, I'd really sort of recommend people to delve into the article and look at that table because it nicely picks out how you could pick up pseudopapilledema versus papilledema. Dr Nevel: Perfect. In your article, you also talk about what's important to think about in terms of causes of papilledema and what to evaluate for. Can you tell us, you know, when you see someone who you diagnose with papilledema, what do you kind of run through in terms of diagnostic tests and things that you want to make sure you're evaluating for or not missing? Dr Mollan: Yeah. So, I think the first thing is, is once it's confirmed, is making sure it's isolated or whether there's any additional cranial nerve palsies. So that might be particularly important in terms of double vision and a sixth nerve palsy, but also not forgetting things like corneal sensation in the rest of the cranial nerves. I then make sure that we have a blood pressure. And that sounds a bit ridiculous in this day and age because everybody should have a blood pressure coming to clinic or into the emergency room. But sometimes it's overlooked in the panic of thinking, gosh, I need to investigate this person. And if you find that somebody does have malignant hypertension, often what we do is we kind of stop the investigational pathway and go down the route of getting the medics involved to help with lowering the blood pressure to a safe level. I would then always think about my next thing in terms of taking some bloods. I like to rule out anemia because anemia can coexist in a lot of different conditions of raised endocranial pressure. And so, taking some simple blood such as a complete blood count, checking the kidney function, I think is important in that investigational pathway. But you're not really going to stop there. You're going to move on to neuroimaging. It doesn't really matter what you do, whether you do a CT or an MRI, it's just getting that imaging pretty much on the same day as you see the patient. And the key point to that imaging is to do venography. And you want to rule out a venous sinus thrombosis cause that's the one thing that is really going to cause the patient a lot of morbidity. Once your neuroimaging is secure and you're happy, there's no structural lesion or a thrombosis, it's then reviewing that imaging to make sure it's safe to proceed with lumbar puncture. And so, we would recommend the lumbar puncture in the left lateral decubitus position and allowing the patient to be as calm and relaxed as possible to be able to get that accurate opening pressure. Once we get that, we can send the CSF for contents, looking for- making sure they don't have any signs of meningitis or raised protein. And then, really, we're at that point of saying, you know, we should have a secure diagnosis, whether it would be a structural lesion, venous sinus thrombosis, or idiopathic intracranial hypertension. Dr Nevel: Wonderful. Thank you for that really nice overview and, kind of, diagnostic pathway and stepwise thought process in the evaluations that we do. There are several different treatments for papilledema that you go through in your article, ranging from surgical to medication options. When we're taking care of an individual patient, what factors do you use to help guide you in this decision-making process of what treatment is best for the patient and how urgent treatment is? Dr Mollan: I think that's a really important question because there's two things to consider here. One is, what is the underlying diagnosis? Which, hopefully, through the investigational save, you'll have been able to achieve a secure diagnosis. But going along that investigational pathway, which determines the urgency of treatment, is, what's happening with the vision? If we have somebody where we're noting that the vision is affected- and normally it's actually through a formal visual field. And that's really challenging for lots of people to get in the emergency situation because syndromes of raised endocranial pressure often don't cause problems with the visual acuity or the color vision until it's very late. And also, you won't necessarily get a relative afferent papillary defect because often it's bilateral. So I really worry if any of those signs are there in somebody that may have papilledema. And so, a lot rests on that visual field. Now, we're quite good at doing confrontational visual fields, but I would say that most neurologists should be carrying pins to be able to look at the visual fields rather than just pointing fingers and quadrants if you're not able to get a formal visual field early. It's from that I would then determine if the vision is affected, I need to step up what I'm going to do. So, I think the sort of next thing to think about is that sort of vision. So, if we have somebody who, you know, you define as have severe sight loss at the point that you're going through this investigational pathway, you need to get an ophthalmologist or a neuro-ophthalmologist on board to help discuss either the surgery teams as to whether you need to be heading towards an intervention. And there are a number of different types of intervention. And the reason why we discuss it in the article---and we'll also be discussing it in a future issue of Continuum---is there's not high-class evidence to suggest one surgery over another surgery. We may touch on this later. So, we've got our patients with severe visual loss who we need to do something immediately. We may have people where the papilledema is moderate, but the vision isn't particularly affected. They may just have an enlarged blind spot. For those patients, I think we definitely need to be thinking about medical therapy and talking to them about what the underlying cause is. And the commonest medicine to use for raised endocranial pressure in this setting is acetazolamide, a carbonic anhydrous inhibitor. And I think that should be started at the point that you believe somebody has moderate papilledema, with a lot of discussion around the side effects of the medicine that we go into the article and also the fact that a lot of our patients find acetazolamide in an escalating dose challenging. There are some patients with very mild papilledema and no visual change where I might say, hey, I don't think we need to start treatment immediately, but you need to see somebody who understands your disease to talk to you about what's going on. And generally, I would try and get somebody out of the emergency investigational pathway and into a formal clinic as soon as possible. Dr Nevel: Thank you so much for that. One thing that I was wondering that we see clinically is you get a consult for a patient, maybe, who had an isolated episode of vertigo, back to their normal self, completely resolved… but incidentally, somebody ordered an MRI. And that MRI, in the report, it says partially empty sella, slight flattening of the posterior globe, concerns for increased intracranial pressure. What should we be doing with these patients who, you know, normal neurological exam, maybe we can't detect any definite papilledema on our endoscopic exam. What do you think the appropriate pathway is for those patients? Dr Mollan: I think it's really important. The more neuroimaging that we're doing, we're sort of seeing more people with signs that are we don't believe are normal. So, you've mentioned a few, the sort of partially empty sella, empty sella, tortuosity of the optic nerves, flattening of the globes, changes in transverse sinus. And we have quite a nice, again, table in the article that talks about these signs. But they have really low sensitivity for a diagnosis of raised endocranial pressure and isolation. And so, I think it's about understanding the context of which the neuroimaging has been taken, taking a history and going back and visiting that to make sure that they don't have escalating headache. And also, as you said, rechecking the eye nerves to make sure there's no papilledema. I think if you have a good examination with the direct ophthalmoscope and you determine that there's no papilledema, I would be confident to say there's no papilledema. So, I don't think they need to necessarily cry doubt. The ophthalmology offices, we certainly are having quite a few additional referrals, particularly for this, which we kind of called IIH-RAD, where patients are coming to us for this exclusion. And I think, in the intervening time, patients can get very anxious about having a sort of MRI artifact picked up that may necessarily mean a different diagnosis. So, I guess it's a little bit about reassurance, making sure we've taken the appropriate history and performed the examination. And then knowing that actually it's really a number of different signs that you need to be able to confidently diagnose raised ICP, and also the understanding that sometimes when people have these signs, if the ICP reduces, those signs remain. You know, we're learning an awful lot more about MRI imaging and what's normal, what's within normal limits. So, I think reassurance and sensible medical approach. Dr Nevel: Absolutely. In the section in your article on idiopathic intracranial hypertension, you spend a little bit of time talking about how important it is that we sensitively approach the topic of potential weight loss for those patients who are overweight. How do you approach that discussion in your clinic? Because I think it's an important part of the holistic patient care with that condition. Dr Mollan: I think this is one of the things that we've really listened to the patients about over the last number of years where we recognize that in an emergency situation, sometimes we can be quite quick to sort of say, hey, you have idiopathic endocranial hypertension and weight loss is, you know, the best treatment for the condition. And I think in those circumstances, it can be quite distressing to the patient because they feel that there's a lot of stigma attached around weight management. So, we worked with the patient group here at IIH UK to really come up with a way of a signposting to our patients that we have to be honest that there is a link, you know, a strong evidence that weight gain and body shape change can cause someone to fall into a diagnosis of IIH. And we know that weight loss is really effective with this condition. So, I think where I've learned from the patients is trying to use language that's less stigmatizing. I definitely signpost that I'm going to talk about something sensitive. So, I say I'm going to talk about something sensitive and I'm going to say, do you know that this condition is related to body shape change? And I know that if I listen to this podcast in a couple of years, I'm sure my words will have changed. And I think that's part of the process, is learning how to speak to people in an ever-changing language. And they think that sort of signpost that you're going to talk about something sensitive and you're going to talk about body shape change. And then follow up with, are you OK with me talking about this now? Is it something you want to talk about? And the vast majority of people say, yes, let's talk about it. There'll be a few people that don't want to talk about it. And I usually come in quite quickly, say, is it OK if I mention it at the next consultation? Because we have a duty of care to sort of inform our patients, but at the same time we need to take them on that journey to get them back to health, and they need to be really enlisted in that process. Dr Nevel: Yeah, I really appreciate that. These can be really difficult conversations and uncomfortable conversations to have that are really important. And you're right, we have a duty as medical providers to have these conversations or inform our patients, but the way that we approach it can really impact the way patients perceive not only their diagnosis, but the relationship that we have with our patients. And we always want that to be a positive relationship moving forward so that we can best serve our patients. Dr Mollan: I think the other thing as well is making sure that you've got good signposts to the professionals. And that's what I say, because people then say to me, well, you know, kind of what diet should I be on? What should I be doing? And I say, well, actually, I don't have professional experience with that. I'm, I'm very fortunate in my hospital, I'm able to send patients to the endocrine weight management service. I'm also able to send patients to the dietetic service. So, it's finding, really, what suits the patient. Also what's within licensing in your healthcare system to be able to provide. But not being too prescriptive, because when you spend time with weight management professionals, they'll tell you lots of different things about diets that people have championed and actually, in randomized controlled trials, they haven't been effective. I think it's that signpost really. Dr Nevel: Yeah, absolutely. So, could you talk a little bit about what's going on in research in papilledema or in this area, and what do you think is up-and-coming? Dr Mollan: I think there's so much going on. Mainly there's two parts of it. One is image analysis, and we've had some really fantastic work out of the Singapore group Bonsai looking at a machine learning decision support tool. When people take fundal pictures from a normal fundus camera, they're able to say with good certainty, is this papilledema, is this not papilledema? But more importantly, if you talk to the investigators, something that we can't tell when we look in is they're able to, with quite a high level of certainty, say, well, this is base occupying lesion, this is a venous sinus thrombosis, and this is IIH. And you know, I've looked at thousands and thousands of people's eyes and that I can't tell why that is. So, I think the area of research that is most exciting, that will help us all, is this idea about decision support tools. Where, in your emergency pathway, you're putting a fundal camera in that helps you be able to run the image, the retina, and also to try and work out possibly what's going on. I think that's where the future will go. I think we've got many sort of regulatory steps and validation and appropriate location of a learning to go on in that area. So, that's one side of the imaging. I think the other side that I'm really excited about, particularly with some of the work that we've been doing in Birmingham, is about treatment. The surgical treatments, as I talked about earlier… really, there's no high-class evidence. There's a number of different groups that have been trying to do randomized trials, looking at stenting versus shunting. They're so difficult to recruit to in terms of trials. And so, looking at other treatments that can reduce intracranial pressure. We published a small phase two study looking at exenatide, which is a glucagon-like peptide receptor agonist, and it showed in a small group of patients living with IIH that it could reduce the intracranial pressure two and a half hours, twenty-four hours, and also out to three months. And the reason why this is exciting is we would have a really good acute therapy---if it's proven in Phase III trials---for other diseases, so, traumatic brain injury where you have problems controlling ICP. And to be able to do that medically would be a huge breakthrough, I think, for patient care. Dr Nevel: Yeah, really exciting. Looking forward to seeing what comes in the future then. Wonderful. Well, thank you so much for chatting with me today about your article. I really enjoyed learning more from you during our conversation today and from your article, which I encourage all of our listeners to please read. Lots of good information in that article. So again, today I've been interviewing Dr Susie Mollan about her article Papilledema Diagnosis and Management, which appears in the most recent issue of Continuum on neuro-ophthalmology.Please be sure to check out Continuum episodes from this and other issues. And thank you to our listeners for joining us today. Thank you, Susie. Dr Mollan: Thank you so much. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Kenyan President William Ruto wrapped up a four-day visit to China on Friday and returned home with a massive new railway deal and more than a billion dollars of investment pledges. Ruto's successful closing of the Phase III extension of the Standard Gauge Railway to the Ugandan border comes after nearly a decade of Kenyan lobbying in China. Also, this week, Eric & Géraud are at the Salzburg Global Forum in Austria, where they joined a diverse group of civil society stakeholders from across Africa to participate in a lively week-long conference on centering an African vision for a new multilateral future. JOIN THE DISCUSSION: X: @ChinaGSProject | @christiangeraud Facebook: www.facebook.com/ChinaAfricaProject YouTube: www.youtube.com/@ChinaGlobalSouth Now on Bluesky! Follow CGSP at @chinagsproject.bsky.social FOLLOW CGSP IN FRENCH AND ARABIC: Français: www.projetafriquechine.com | @AfrikChine Arabic: عربي: www.alsin-alsharqalawsat.com | @SinSharqAwsat JOIN US ON PATREON! Become a CGSP Patreon member and get all sorts of cool stuff, including our Week in Review report, an invitation to join monthly Zoom calls with Eric & Cobus, and even an awesome new CGSP Podcast mug! www.patreon.com/chinaglobalsouth

Have you wondered why having more drug options matters for chronic rhinosinusitis with nasal polyps? In the inaugural episode of our new series, The Itch Review, co-hosts Kortney and Dr. Payel Gupta, along with special guest Dr. Michael Blaiss, unpack the journal article "Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps," published in the New England Journal of Medicine on March 1, 2025. This article is about the Phase III WAYPOINT trial of tezepelumab. Already approved for severe asthma, this once-monthly biologic is now showing promise in chronic rhinosinusitis with nasal polyps (CRSwNP). Over 52 weeks, 408 patients were randomized to receive 210 mg of tezepelumab every four weeks or placebo. Researchers tracked nasal-polyp scores, congestion, sense of smell, and rates of rescue surgery. In this episode, we provide a brief overview of what CRSwNP is, why inflammation drives polyp formation and how blocking TSLP fits into today's biologics options. We'll walk you through the WAYPOINT Phase III design, explain the primary and secondary endpoints, and translate the headline results into what they mean for real-world patients who've exhausted their treatment options. ➡️ Get the infographic here. What we cover in our episode about treating chronic rhinosinusitis with nasal polyps with tezepelumab CRSwNP basics & tezepelumab mechanism of action: How nasal polyps form and why targeting TSLP can reduce inflammation WAYPOINT design: 52-week, placebo-controlled Phase III study in 408 patients  Primary endpoints: Mean change in nasal polyp score and nasal-congestion score Secondary endpoints: Smell recovery, need for rescue surgery or systemic steroids, and quality-of-life measures Why choice matters: Every CRSwNP patient responds differently, and having more treatment options means more chances to find the right fit   Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

While much of the country was off celebrating Easter and Passover this weekend, the FDA—and its new leader Marty Makary—were busy making news. Makary, who was confirmed as FDA commissioner last month, gave his first major interview, where he unveiled a new regulatory pathway for rare disease therapies and addressed the “epidemic of distrust” he feels is imperiling the agency. Makary also shared his thoughts on the conflicts of interest he sees between the FDA and pharma industry, highlighting a new directive to ban industry representatives from serving on the agency's advisory committees—a move experts believe will have minimal impact in reducing COIs.Makary also touched on vaccines and what he believes to be the cause of autism. On this, he was more restrained than his boss, HHS Secretary Robert F. Kennedy Jr., who continues to insist on re-investigating what he believes is a link between autism and vaccines. The interview comes as more former FDA officials sound the alarm about the changes happening within the agency.Elsewhere on the policy front, President Donald Trump continues to threaten tariffs on pharma products. In response, two more companies, Roche and Regeneron, are committing billions of dollars to enhance their U.S. footprints. They join Novartis, J&J and Eli Lilly in this regard, with the latter additionally promising to manufacture its investigational oral obesity drug orforglipron in the U.S.That announcement followed the news that orforglipron generated “injectable-like efficacy” in a Phase III diabetes trial. Lilly intends to submit for approval of the pill for weight management by the end of this year and diabetes in 2026. Not to be outdone, chief rival Novo Nordisk revealed Saturday that it has already filed for FDA approval of an oral formulation of its own blockbuster, semaglutide, for overweight and obesity.Finally, make sure to check out this week's edition of BioPharm Executive where we take a deep dive into another sizzling space—transthyretin amyloid cardiomyopathy (ATTR-CM)—and find out which pharma CEO has the biggest golden parachute.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. In a recent interview with former Fox News journalist Megyn Kelly, FDA Commissioner Marty Makary discussed a potential new mechanism-driven pathway for expedited rare disease approvals, as well as the possibility of certain environmental factors contributing to autism. Despite Makary's announcement of a directive to limit industry participation in the FDA's advisory committees, industry involvement is actually required by a 1997 law, and banning industry representatives would not have a significant impact. Additionally, the FDA recently approved Sanofi/Regeneron's Dupixent for chronic hives after initially rejecting it, and Lilly has promised to manufacture a weight-loss pill in the US following a Phase III win. The newsletter also includes other news stories, opinions, and upcoming events in the biopharmaceutical industry.

Die Abenteuer-Reihe von Die Hohe Republik ist ein stetes Auf und Ab. Während sie in der ersten Phase noch mit Metaphern und intelligenter Verwebung überzeugte, scheiterte sie in der zweiten Phase an ihrer Belanglosigkeit. Doch in der dritten Phase geht es endlich zurück zu den alten Charakteren und damit zurück zu alter Stärke - oder? Darüber reden Ines und Tobias in dieser Ausgabe des JediCast und zeichnen ein eher enttäuschtes Bild. Die Figuren sind zu undefiniert, treten beliebig in den Vorder- und Hintergrund. Neue Figuren werden kaum bis gar nicht etabliert, die Handlung ist zerstückelt und unfokussiert und nicht mal mehr die metaphorische Botschaft aus der ersten Phase verfängt noch. Wieso all das so ist, soll dieser Podcast klären als auch die Frage, warum ausgerechnet Zeen zur BrideZilla wird! Zeitmarken spoilerfreier Teil 00:00:00 - Begrüßung 00:02:08 - Eindruck von der bisherigen Reihe 00:04:02 - Das Amnesie-Problem 00:06:36 - Die Zeichnungen Spoilerteil 00:09:43 - BrideZilla 00:15:00 - Kennt man die? 00:19:46 - Ein Hauch von Politik 00:24:16 - Am Anfang war die Amnesie 00:27:53 - Krix macht nix? 00:30:44 - Sevran all along? 00:34:48 - Keine Fallhöhe 00:36:00 - Niv und das Nichtstun 00:37:24 - Frage der Zugänglichkeit 00:44:50 - TriVaEriadu 00:49:33 - Düstere Aussichten 00:54:00 - Major Tom zu wörtlich genomm' 00:58:49 - Lula und die falsche Symbolik Blick in die Datenbank Die Hohe Republik - Abenteuer, geschrieben von Daniel José Older, erschien in mehreren Einzel-Arcs: Unter Die Hohe Republik - Abenteuer, Band 8 wurden gesammelt von Panini: What the Mikkian Wants The Ballad of Tartak Vil Now or Never Unter Die Hohe Republik - Abenteuer, Band 9 wurden gesammelt von Panini: Eriadu Games The Evacuation Run Tarkin Family Business Die Rezensionen Ines hat die einzelnen Ausgaben im Rahmen der Dark-Horse-Rezensionen behandelt. Ihre Meinung zur Handlung ist dabei - surprise - deckungsgleich mit der im Podcast. Zu viele Charaktere, die nicht eingeführt werden und zu wenig eigentliche Handlung, machen das Ganze beliebig und schlechter als in der ersten Phase. Tobias hat sich des ersten Panini-Bands angenommen und wird sich dem zweiten noch widmen. Gerade die viele Zeit, die gebraucht wird, um wieder zu einem Status Quo zu kommen, haben ihm den ersten Band madig gemacht. Der zweite wird insgesamt durch fehlenden Fokus auf eine Handlung und beliebige Hauptfiguren nicht viel besser abschneiden. Den JediCast abonnieren Wir sind auf allen gängigen Podcast-Plattformen vertreten! Abonniert uns also gerne auf Spotify, Apple Podcasts, Google Podcasts (etc.), oder fügt bequem unsere Feeds in euren präferierten Podcast-Player ein. Alle Links dazu findet ihr oben unter dem Player verlinkt sowie auch jederzeit unter dem Audioplayer in der rechten Sidebar. Wir freuen uns auch immer über Bewertungen auf den jeweiligen Podcast-Seiten. Falls ihr umfangreichere Anmerkungen habt, schreibt auch gerne eine Mail an podcast@jedi-bibliothek.de! Eure Meinung Wie seid ihr in die dritte Phase mit Lula, Zeen, Qort, Farzala, und Hauptfigur 5 bis 99 gestartet? Hat euch die Handlung(en) mitgenommen oder sucht auch ihr - wie Theseus - Ariadnes roten Faden? Schreibt es uns gerne in die Kommentare. Wenn ihr uns unterstützen wollt, könnt ihr das seit neuestem über unseren Buymeacoffee-Link tun. Star Wars: Die Hohe Republik ist ein mehrjähriges Buch- und Comicprogramm, das hunderte Jahre vor den Skywalker-Filmen spielt und die Jedi in ihrer Blütezeit zeigt. Weitere Infos, News, Podcasts und Rezensionen gibt es in unserem Portal und in der Datenbank. Beachtet auch unsere Guides zur Lesereihenfolge von Phase I, Phase II und Phase III.

It was a solid start to the week, with the ASX 200 up 102 points to 7749 (1.3%). Strong banks and resources are taking us up. The Big Bank Basket rallied to $248.77 (+1.6%). CBA was up 1.7%, and WBC was up 1.6%. Insurers also better with MQG flat as some downgrades coming through. REITs rallied hard, GMG up 2.4% and SCG up 1.8%. Industrials were better but lagged, WES up 1.1% and SGH up 2.7% with the supermarkets flat, retail rose, LOV up 2.4% and JBH rallying 2.4%. Travel stocks were a little better, tech doing well, WTC up 3.1% and XRO rising 2.3% with the All-Tech Index up 2.1%. TLS slipped a little. In resources, iron ore miners rose, BHP up 2.7%, RIO up 1.4% with the gold miners pushing up although gold saw some profit taking. NEM up 4.5% with EVN up 2.6%. MIN had a good day as some shorts covered again, PLS rallied 3.3% with IGO up 3.2%. Oil stocks inched up WDS up 1.1% and STO up 1.8% with uranium and coal stocks better, WHC up 4.8% and DYL up 3.9%. In corporate news, NEU jumped 21.1% on a positive end point for its Phase III trial. DEG up 1.6% as GOR will vote in favour of the NST deal. Nothing locally on the economic front.  Asian markets better, Japan up 1.6%, HK up 2.1% and China 0.3% higher. 10-year yields steady around 4.41%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy.Kristian Reich is co-founder and CSO of MoonLake Immunotherapeutics. After a long and distinguished career as a clinician and researcher, Kristian helped to launch MoonLake in 2021 and quickly helped move their lead candidate to the clinic. Now, on the verge of Phase III trials, he joins 'Beyond Biotech' to talk nanobodies, innovation, serendipitous science, and the power that comes from never stopping to dream.01:04               Meet Kristian Reich05:26               Excited by the science of nanobodies07:13               MoonLake's mission13:12               Milestones at MoonLake15:24               Introduction to nanobodies17:55               Serendipitous science19:46               How nanobodies work23:18               Global prevelance of immune conditions24:31               The impact on patients27:09               Nanobodies in the clinic31:19               Manufacturing challenges, regulatory challenges34:04               Working with top pharma35:55               The future of nanobodies37:42               The future of MoonLake39:10               Don't stop dreamingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Send us a textDr. Kilian Kelly, Ph.D. is Chief Executive Officer and Managing Director of Cynata Therapeutics ( https://cynata.com/ ), a stem cell and regenerative medicine company that is known for its proprietary Cymerus platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies.Unlike traditional MSC therapies that rely on multiple donors, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities from a single donor – making the opportunities endless and attractive from a manufacturing standpoint. The company has completed Phase I studies for Graft vs Host disease & Diabetic Foot Ulcers and have a number of Phase II, and even have a Phase III clinical trial, in progress.Dr. Kelly has over 20 years' experience in biopharmaceutical research and development, including almost 15 years focused on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.Dr. Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca. Dr. Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a Ph.D. in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD.Dr. Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialization of Regenerative Medicine (CCRM) Australia.#KilianKelly #CynataTherapeutics #InducedPluripotentStemCells #MesenchymalStemCells #Immunomodulation #Immunoregulation #Mesenchymoangioblasts #GraftVersusHostDisease #GVHD #MSC #iPSC #IschaemicHeartDisease #Osteoarthritis #AcuteRespiratoryDistressSyndrome #ARDS #Inflammation #Secretome #Paracrine #RegenerativeMedicine #DiabeticWounds #KidneyTransplantation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

In this episode, Ayesha spoke with Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, a company focused on developing treatments for autoimmune diseases. Dr. Fordyce founded Vera in 2016 as an entrepreneur in residence at Kleiner Perkins Caufield and Byers, took the company public in 2021 and has advanced its lead molecule through a successful Phase II trial in IgA nephropathy. The company is on track to read out its Phase III results next quarter. Along the way, Dr. Fordyce has built a world class team of drug developers and raised over $1 billion in capital. Dr. Fordyce previously worked in clinical development leadership roles at Gilead Sciences in the 2010s, driving innovation in treatments for HIV and hepatitis. Dr. Fordyce received his BA from Harvard University and MD from Harvard Medical School, trained in Internal Medicine and served as Chief Resident at NYU Bellevue. Dr. Fordyce currently serves on the Board of Directors and as Treasurer of the Albert and Mary Lasker Foundation. Tune in to hear Dr. Fordyce discuss new innovations in therapies for autoimmune diseases like IgA nephropathy and the work he is leading at Vera Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

The ASX 200 rose 6 points to 7937 (0.1%) in quiet trade ahead of the Budget. Banks were firm with the Big Bank Basket at $242.34 (+1.5%). Tariff proof fenced perhaps. CBA up 1.4% and insurers better too, QBE up 0.3%. REITs were a little mixed, GMG down 0.6% and SCG rising 0.6%. RPL was smashed 14.8% on news from OPT that it had missed Phase III end point. RPL owns 32% of the biotech. In the industrials, WOW and COL both giving back some of the optimism from Friday's ACCC report. Tech stocks also under pressure, WTC down 2.9% and 360 falling 4.4%. The All-Tech Index down 0.5%. Retail weaker, PMV down 2.9% with NCK off 2.0% and MYR down 2.1%. WES rose as did JBH.Resources were a mixed bag of lollies. BHP fell 0.6% with FMG up 3.2% on some broker upgrades. Gold miners were mixed, VAU down 3.2% with NST off 1.3% and BGL dropping 12.8% on change in substantial holding. MIN bounced 6.9% as the haul road reopened. Oil and gas flat, coal eased, NHC down 4.4% and WHC off with uranium sellers back. BOE down 3.5% and DYL falling 1.8%. In corporate news, JHX announced a huge US merger and dropped 14.5% on the news. HLI fell 25.6% as CBA said it may not renew its contract. SM1 curdled 12.0% on unimpressive results.Nothing on the economic front. Asian markets flat. 10-year yields back up to 4.42%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 14 March 2025. In this episode: Roche's big new obesity deal; J&J opts out of next-gen Darzalex; Arvinas and Pfizer's protein degrader misses Phase III endpoint; Kelun wins first TROP2 ADC approval in lung cancer; and big name brands poised to lose US exclusivity. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-QOIAKBVZ2FDQ7NL2SFMWK66HP4/ This episode was produced using AI text-to-voice and voice emulation software. Let me know your views: ian.haydock@citeline.com. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

As we mark five years since the World Health Organization officially declared the COVID-19 pandemic, the BioSpace editorial team reflects on the health crisis of a generation and how it changed us—and the biopharma industry. While companies like Pfizer, BioNTech and Moderna raked in billions from their vaccines, J&J and Novavax struggled to capture a significant piece of the market.   Five years later, much has changed. A substantial number of us now work from the comfort of our homes—though that may be changing for some in the life sciences—and biopharma has a new obsession: obesity. In this space, Novo Nordisk has had a rough week, reporting lower-than-expected results from a second straight trial of its next-gen weight loss drug CagriSema. And in an effort to protect revenues from its blockbuster weight-loss drug Wegovy, Novo jumped into the legal battle between the FDA and compounding pharmacies over the regulator's decision to declare the shortage of Wegovy over. Viking Therapeutics had a better week, securing “multiple metric tons” of its investigational obesity medication VK2735 in a deal with CordenPharma. Meanwhile, companies continue to tackle adverse events associated with GLP-1s.  Another space that has seen its fair share of failures in the past couple of years is depression. The latest flop comes from J&J, which announced it would discontinue its a kappa opioid receptor blocker aticaprant after a disappointing Phase III readout. J&J joins Biogen and Sage Therapeutics, Relmada Therapeutics and Alto Neuroscience, all of whom have suffered regulatory misses or trial flops. Finally, two of Donald Trump's healthcare nominees, Marty Makary and Jay Bhattacharya, sailed through their confirmation hearings in the Senate last week. Both are up for confirmation on Thursday.   

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. AbbVie has recently entered the obesity market through a deal with Gubra for Amylin, worth up to $2.2 billion. This move positions AbbVie among industry leaders like Novo Nordisk and Eli Lilly. The focus on redefining obesity as a chronic disease is gaining momentum, with recent FDA documents and The Lancet Diabetes & Endocrinology commission highlighting the importance of maintenance treatment. In immuno-oncology, experts are searching for the next breakthrough beyond Keytruda and Yervoy. Novel targets, combinations, and pre-emptive immunization are being explored as potential areas of growth. The upcoming World Orphan Drug Congress in 2025 will gather industry leaders to discuss the future of orphan drug development and rare disease care. Positive developments have been reported for Biogen and Eisai's Leqvio in Europe, AstraZeneca and Amgen's Phase III win for Tezspire, and advancements in non-opioid painkillers by Lexicon. The text also discusses the maturation of immuno-oncology, the potential of mRNA technology in rare diseases, recent FDA approvals for rare disease treatments, the evolving mindset towards treating obesity as a chronic disease, and updates on FDA-related news. Lastly, job opportunities in the biotech industry are available at AbbVie, Moderna, Arvinas Inc., and Sonothera. Share your input on topics to cover in the biopharma industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The Epic Act has been reintroduced in Congress to remove the IRA's 'pill penalty', with hopes for positive changes. However, budgetary constraints may make it challenging for the current administration to make significant amendments to the IRA. As money continues to flow into weight loss drugs, physicians are prioritizing efficacy and access. Emalex is moving towards FDA approval after a successful Phase III trial for Tourette Syndrome. AstraZeneca also received positive Phase III results for an oral breast cancer drug. SpringWorks Therapeutics successfully turned a Pfizer 'ghost drug' into a victory by keeping a rare disease program alive with the help of advocacy groups. This success story has led experts to believe that this method could be applied to other rare diseases as well. The company serves as a case study for how to mine biopharma's IP storeroom for rare disease drugs.Meanwhile, weight loss doctors are seeking better GLP-1 medications, but are facing challenges with high prices and supply issues. Trump is threatening big pharma with tariffs unless they reshore manufacturing. Bluebird Bio is facing financial challenges and may go private in a deal valued at $30 million. Compounders are suing the FDA over declaring a shortage of certain drugs, while the FTC is tightening merger rules despite the Trump administration's pro-industry stance.These updates show the ever-evolving landscape of the pharmaceutical and biotech industries. Stay tuned for more important news and developments in the field.

Sal talks some The High Republic Adventures comics! Saber for Hire! Crash Landing! Crash and Burn! 2025 Annual! Ty and her squire! Jom and Kip must be found! Someone from Ty's Jedi past? Li'l bay Lene Kostana! Can Krix Kamerat help bring down Marchion Ro? Jedi younglings watching Socorro Jayme! Driggit Parse heart to heart with Emelsine Tarkin! Can Churo the Hutt save Nal Hutta? Baron Boolan and the Children of the Storm Vernestra Rwoh finds her pathCheck out the Rogue Rebels The High Republic playlist here!⁠⁠Check out the Rogue Rebels Star Wars comics playlist here!⁠Follow us EVERYWHERE!⁠⁠⁠@TheRogueRebels on Bluesky!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠IG: @TheRogueRebels ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Rogue Rebels on FB⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Watch The X22 Report On Video No videos found Click On Picture To See Larger Picture Trump has now ended the attack on gas stoves, everything that Biden has done is being reversed. Lee Zeldin found the money and is returning to the people. Politico admits the job numbers are fake. Trump has begun the parallel economy, tariffs are being implemented. The end of the Fed is coming. The [DS] players are panicking, the people are now seeing that there are rats everywhere. DOGE is setting up a transparent system so the people can see it all. This was not just another 4 year election this was a crossroads to see if can keep the country. Phase I and II happening right now. Once the people see the criminals and the treason that they have committed we will be moving to Phase III, a traitors justice.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy Trump Admin Formally Ends Biden's War on Gas Stoves The Consumer Product Safety Commission is formally ending a review that it initiated during the Biden administration to assess the potential health risks posed by gas-powered stovetops. In a statement to the Washington Free Beacon, Consumer Product Safety Commission acting chairman Peter Feldman said he considers the matter "concluded" and emphasized that the federal government should not interfere with consumer choice. Feldman's comments effectively put an end to a years-long process that critics feared would lead to a broad ban on gas stoves. " "I became Acting Chairman of the United States Consumer Product Safety Commission in January 2025, shortly after President Trump's inauguration," he continued. "So long as I have a say in the matter, the CPSC is out of the gas-stoves-banning business. The agency has no plans to advance such a rule." Source: freebeacon.com EPA Chief Lee Zeldin Pledges to Recover $20 Billion Lost by Biden Administration for Climate Projects Lee Zeldin, EPA Chief for the Trump administration, has pledged to recover the $20 billion in taxpayer funds lost by the Biden administration to climate projects. Zeldin made the announcement in a video posted to social media on Wednesay when he charged the Biden administration of “throwing gold bars of the Titanic” in relation to the money lost on climate projects that he said was a “rush job with reduced oversight.” “The days of irresponsibly shoveling boatloads of cash to far-left activist groups in the name of environmental justice and climate equity are over,” Zeldin said. “The American public deserves a more transparent and accountable government than what transpired these past four years.” Source: breitbart.com https://twitter.com/epaleezeldin/status/1889840040622321778 Rep. Jan Schakowsky Suggests Women Might Not Pursue Jobs in Manufacturing Because “Man” is in the Name (Video) Rep. Jan Schakowsky (D-IL) pushed a bizarre explanation for why women might not pursue jobs in manufacturing. Schakowsky made her remarks on Wednesday during a Commerce, Manufacturing and Trade subcommittee hearing entitled “AI in Manufacturing: Securing American Leadership in Manufacturing and the Next Generation of Technologies.” Schakowsky suggested that perhaps the reason fewer women choose a career in manufacturing is that the term has the word “man” in it. https://twitter.com/libsoftiktok/status/1889833714974416938?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1889833714974416938%7Ctwgr%5E405aa74609e691f5897438e7cd78045186bc95f1%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2025%2F02%2Frep-jan-schakowsky-suggests-women-might-not-pursue%2F Source: thegatewaypunidt.com

We saw more action on the M&A front this week as Novartisbought back its blood thinner abelacimab and the rest of Anthos Therapeutics for up to $3.1 billion and still ahead, a potential buyout of SpringWorks Therapeutics by Merck KGaA, which confirmed it's in “advanced discussions” with the biotech. Meanwhile, Eli Lilly signed aglobal licensing deal for a MASH asset with South Korea's OliX Pharmaceuticals.As Q4 and full-year 2024 earnings continue to roll in, BMS, Eli Lilly,Novo Nordisk, AstraZeneca, Eisai, Vertex and Gilead all reported their results in the past week. Notably, BMS continues to reorganize, now targeting an additional $2 billion in savings through 2027, and AstraZeneca axed two rare disease drugs from its $39 billion acquisition of Alexion. When it comes to revenue growth, Novo's Wegovy and Lilly's Zepbound continue to climb at a striking pace—a phenomenon that has at times driven the weight loss drugs into shortage and spawning a controversialshadow market of off-brand versions.Speaking of controversy, Regeneron is suing its Dupixent partner Sanofi, claiming the French pharma has failed to provide it with adequate information regarding sales of the blockbuster anti-inflammatory drug—which missed analyst expectations in Q4.On the clinical side, the pulmonary fibrosis space continues to see positive results, with Boehringer Ingelheim notching its second Phase III win in six months for nerandomilast. It wasn't all good news, however, as Pliant Therapeutics suspended dosing and enrollment in a Phase IIb/III study of its idiopathic pulmonary fibrosis candidate, causing its stock to crash.Finally, BioSpace released a special edition of ClinicaSpace this week focused on the resurgent cardiovascular space—just in time for Valentine's Day! Sign uphere to receive your copy.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Bristol Myers Squibb is seeking to broaden the use of its CAR T cell therapy, Breyanzi, to address marginal zone lymphoma as a strategy to offset losses from exclusivity. In other news, Boehringer Ingelheim has seen promising results in a Phase III trial for its lung fibrosis drug, randomilast, aimed at progressive pulmonary fibrosis. However, Pliant has experienced a stock decline following the halt of its Phase IIb/III study for idiopathic pulmonary fibrosis. Additionally, Vertex has received FDA approval for its non-opioid pain treatment, while AbbVie has secured approval for a new antibiotic. Bain's acquisition of Tanabe for $3.3 billion is also making headlines. Regeneron is currently in a legal battle with Sanofi over the Dupixent pact, and Equillium's itolizumab is undergoing testing against Humira for ulcerative colitis. On the horizon, Acelyrin and Alumis are joining forces to address immune-mediated diseases, while Eisai is seeking subq approval for Leqembi due to sluggish US sales. Job opportunities are available at ATCC, AbbVie, Regeneron Pharmaceuticals, and Dren Bio.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis plans to continue making bolt-on deals in 2025 after a successful year in 2024. AbbVie is regrouping after a mid-stage schizophrenia drug failure. Vertex's non-opioid pain drug has been approved by the FDA. Biotechs are turning to the courts to fight off potential buyers. Other news includes drug pricing under Trump, RFK Jr.'s scrutiny over vaccines, Blackstone's new fund for life sciences, and layoffs at various companies.The FDA has approved Vertex's Journavx (suzetrigine) as the first non-opioid pain signal inhibitor in over two decades. This drug offers patients a non-opioid option for managing acute pain by targeting and binding to the nav1.8 voltage-gated sodium channel. The approval of Journavx comes after Vertex's $7.4 billion opioid settlement and is part of a new wave of medicines aiming to provide effective pain relief without the risks associated with opioids. The FDA's decision was based on positive results from Phase III trials, showing significant improvements in pain scores for patients who had undergone bunionectomy and tummy tuck surgeries. This approval marks a milestone in the development of new pain medications and signals a potential shift towards safer alternatives to opioids for pain management.

AGORACOM Talks! Here's a quick rundown of the latest updates from standout small-cap companies making big moves this week. AISIX Solutions (TSXV: AISX) AISIX Solutions records its first revenue of 2025, marking a major milestone in AI-driven climate risk intelligence. The company's integration into Eli Report enhances real estate decision-making with climate risk assessments, reinforcing its leadership in predictive analytics for property investments. Goliath Resources (TSXV: GOT) McEwen Mining makes a $10M strategic investment in Goliath Resources, recognizing the high-grade gold potential of the Surebet Discovery in British Columbia's Golden Triangle. With visible gold in 92% of drill holes and exceptional grades, Goliath is gaining traction as a major player in gold exploration. HPQ Silicon (TSXV: HPQ) HPQ Silicon's Novacium subsidiary files a patent for aluminum recycling technology, transforming Black Aluminum Dross into green hydrogen and valuable resources. With strong interest from European recyclers, this innovation could revolutionize the aluminum industry and boost sustainability efforts. PyroGenesis (TSX: PYR) PyroGenesis lands a $2.5M contract to supply gas purification technology for a major waste-to-energy project in the U.S. Their advanced plasma tech will enhance renewable natural gas production, reducing emissions and reinforcing their role in clean energy solutions. Power Nickel (TSXV: PNPN) Power Nickel launches its 2025 winter drilling campaign after discovering high-grade nickel, copper, cobalt, platinum, and palladium in Quebec's Nisk Project. With three drill rigs set to expand its resource base, the company aims to uncover significant mineralization in new target zones. Abitibi Metals (CSE: AMQ) Abitibi Metals reports strong drill results at its B26 deposit, reinforcing its high-grade copper-gold potential. The latest assays confirm mineral continuity and pave the way for 20,000 meters of additional drilling in Phase III, strengthening its position in Quebec's mining sector. For breaking updates on small-cap companies making waves, follow AGORACOM on our Spotify podcast. Don't miss the stories shaping today's markets.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sage has rejected Biogen's unsolicited buyout offer and will seek strategic alternatives. Biogen and Eisai have received approval for a monthly maintenance regimen for Alzheimer's drug Leqembi. Veru's drug has shown promise in sparing lean mass in overweight adults on Wegovy. The Duchenne muscular dystrophy space is on the verge of a pivotal era with several companies developing investigational therapies. Akero has rebounded in a mid-stage trial, Daiichi Sankyo is optimistic for 2025, and Allakos is cutting its workforce. The text discusses the advancements in the Duchenne Muscular Dystrophy (DMD) space as it enters a pivotal era, with companies such as Capricor Therapeutics, Wave Life Sciences, and RegenxBio working on investigational therapies to address unmet needs. It also mentions Daiichi Sankyo's recent success with the approval of Astrazeneca-partnered Dato-DXD. Additionally, new treatments are in development for Achondroplasia to challenge Biomarin's Voxzogo. Novo's obesity drug shows promising results, Merck's Keytruda combo fails in a Phase III trial for GI cancer, and Tris Pharma wins late-stage for a non-opioid painkiller. The text also invites feedback from readers on topics they would like to see covered in the future.

Appreciative Rest is Taking in and Appreciating the beauty around you. (Phase III of The UnVeiling Method - 7 Forms of Rest Other Than Sleep) Creative rest practice is the active form of appreciative rest where you are creating by painting, writing, sewing, singing, playing an instrument etc. Signs of Appreciative Rest Depletion: ●     focus on the needs of others and don't consider your needs a       priority. ●     talk yourself out of self-care as if you don't deserve being cared for. ●     feel you are being selfish whenever you consider doing something       for yourself. ●     often feel your work is not of value or that others do not appreciate       your contributions. ●     find it difficult to enjoy things in nature or in your environment. How are you being creative in your life? What's your favorite way to express your creativity? How do you feel when you are being creative? What do you notice when you haven't spent time creating like you'd like to? Myrko Thum quote: “The present moment is the only thing where there is no time. It is the point between past and future. It is always there and it is the only point we can access in time. Everything that happens, happens in the present moment. Everything that ever happened and will ever happen can only happen in the present moment. It is impossible for anything to exist outside of it.” Active forms of creative rest allow us to be in the present moment and to allow space for our mind, body and higher self to align. Spend 10 - 15 minutes on your chosen creative rest.  Set a timer on your phone if that helps. At the end of your creative rest, use the reflection questions in the notes below to guide you further. Reflection Questions for after the creative rest time: What did you notice about how that 10 - 15 minutes felt, was it fast or slow? How much did you create vs how much you expected yourself to create in this time?  Was it more or less? What did you notice about your thoughts before you began and now? How do you feel now? Loving side quest for this week: Take a moment to schedule in 10 min to spend in creative rest this week. Join the Spicy Pepper List to be the first notified when we offer Open House in our UnVeiler Community to experience sessions just like this one.  Sign up for the Spicy Pepper List HERE: https://energyuplevel.kit.com/9bd5c71047

Sal talks The High Republic Phase III comics! A new 2025 Star Wars series coming! Jedi Knights and Legacy of Vader! Keeve Trennis is back in action! Wait Lourna Dee is here too? The Children of the Storm in action! Hunted! But why? A trandoshan with a lightsaber?? The return of Tey! Baron Boolan and his monsters!! Check out the Rogue Rebels The High Republic playlist here! Check out the Rogue Rebels Star Wars comics playlist here! Click here to subscribe wherever you listen to podcasts! Follow us EVERYWHERE! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠IG: @TheRogueRebels ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Tweets @RogueRebelsFam ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Rogue Rebels on FB⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna has received nearly $600 million in funding from HHS for mRNA-based bird flu vaccines, with the goal of having these vaccines ready before potential human outbreaks. As 2025 begins, there is a predicted shift towards investments in immunology, inflammation, obesity, neuromuscular, kidney, and cardiovascular diseases. Sage is suing partner Biogen after an unsolicited takeover offer, and Astrazeneca and Daiichi Sankyo's ADC has won its first approval despite mixed data. Analysts and biotech executives also highlight a pivot towards cell therapy for autoimmune diseases and continued interest in next-generation obesity drugs.Analysts and biotech executives predict a focus on immunology, inflammation, obesity, neuromuscular, kidney, and cardiovascular diseases in 2025. Cell therapy is shifting towards autoimmune diseases. Key stories include setbacks for the Astrazeneca/Daiichi Sankyo antibody-drug conjugate, new treatments for celiac disease gaining traction, and advancements in reframing multiple myeloma from fatal to treatable. Novo Nordisk's high-dose Wegovy shows increased weight loss in a Phase III trial, AstraZeneca receives full FDA approval for a lymphoma treatment, and Pfizer is optimistic about an obesity pill. Johnson & Johnson makes a major neuro play with a $14.6 billion buyout.

Donald Trump was sworn in as the 47th president of the United States on Monday, bringing with him a host of healthcare nominees and potential changes to the FDA, M&A and drug pricing. The new administration was a key focus point at the 2025 J.P. Morgan Healthcare Conference last week, where Annalee Armstrong spoke to executives from several companies about what they're expecting from a second Trump term. Also at JPM, Mirador Therapeutics CEO Mark McKenna boldly predicted that 2025 would see the return of the megamerger. Speaking of M&A, Annalee spoke with leaders from Biogen, who declined to address the company's unsolicited takeover bid for Sage Therapeutics. For its part, Sage sued Biogen last week, “seeking preliminary injunctive relief to enforce a standstill agreement.” Meanwhile, Gilead CEO Daniel O'Day addressed the split of Galapagos—a company Gilead has poured more than $5 billion into since 2019. Check out more personal stories from JPM here. In the obesity space, Novo Nordisk reported data from a Phase III trial showing that a high dose of Wegovy elicited more weight loss than the approved regimen—but still fell short of results posted by Eli Lilly's Zepbound. Relatedly, Wegovy and sister drug Ozempic are both on the list of the next fifteen drugs whose prices could be negotiated under the Inflation Reduction Act. Finally, the FDA on Friday made its first high-profile decision of the year, greenlighting AstraZeneca and Daiichi Sankyo's Dato-DXd—now Datroway—to treat certain types of advanced breast cancer. The approval is the first for the highly touted antibody-drug conjugate, which is also under FDA review for EGFR-mutated non-small cell lung cacner. Analysts expect 2025 to be a pivotal year for the ADC.

MS symptoms can worsen, and relapses can occur. And when that happens, how do you know whether you require immediate medical care? When is it time to go to the hospital? Dr. Kalina Sanders joins me to talk about when it's time to seek immediate medical care for MS. Dr. Sanders is a board-certified neurologist who specializes in multiple sclerosis and spasticity management at Baptist Health in Jacksonville Beach, Florida. We're also talking about MS care in the United Arab Emirates with Professor Bassem Yamout, the President of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis. We'll explain why Bayer's new MRI contrast agent is good news for people with MS. We'll tell you about a new Federal Trade Commission report that calls out Pharmacy Benefit Managers for inflating the price of generic specialty drugs by thousands of percent. We'll share the details of a study that shows the profound impact of menopause on MS. And we're sharing two different opportunities for you to participate in MS research. We have a lot to talk about! Are you ready for RealTalk MS??! A word about Facebook posts  :22 This Week: Worsening symptoms? Relapse? When is it time to go to the Emergency Room?  1:46 FTC reports Pharmacy Benefit Managers have marked up generic specialty drugs 1000s of percent  2:20 Bayer's new MRI contrast agent contains 60% less gadolinium  4:57 Professor Bassem Yamout discusses MS in the United Arab Emirates  6:48 Study reveals menopause significantly increases the speed of disability worsening and brain cell damage in women with MS  15:08 Two opportunities for you to participate in MS research  17:38 Dr. Kalina Sanders explains when it's time to seek immediate medical care for MS     19:54 Share this episode  31:42 Have you downloaded the free RealTalk MS app?  32:02 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/386 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com RealTalk MS on YouTube https://www.youtube.com/@RealTalkMS Federal Trade Commission Interim Report on Pharmacy Benefit Managers and Specialty Generic Drugs https://www.ftc.gov/reports/specialty-generic-drugs-growing-profit-center-vertically-integrated-pharmacy-benefit-managers Bayer Announces MRI Contrast Agent Gadoquatrane Meets Primary and Main Secondary Endpoints in Pivotal Phase III Studies https://www.businesswire.com/news/home/20250109869429/en/Bayers-investigational-MRI-contrast-agent-gadoquatrane-meets-primary-and-main-secondary-endpoints-in-pivotal-Phase-III-studies STUDY: Association of Menopause with Functional Outcomes and Disease Biomarkers in Women with Multiple Sclerosis https://www.neurology.org/doi/10.1212/WNL.0000000000210228 PARTICIPATE IN MS RESEARCH: Psychometric Properties of Sexual Difficulties Scales in People Living with Multiple Sclerosis https://qualtrics.kcl.ac.uk/jfe/form/SV_br1fVoYGqXnLooK PARTICIPATE IN MS RESEARCH: Efficacy and Safety Study of Frexalimab in Adults with Nonrelapsing Secondary Progressive Multiple Sclerosishttps://www.sanofistudies.com/SR0A/ Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 386 Guests: Professor Bassem Yamout, Dr. Kalina Sanders Privacy Policy

On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss how clinical researchers can leverage proteomics for drug development. Some of the themes covered in this episode include:· Proteomics and pre-clinical models· How proteomics can drive patient selection· Choosing the right end points in clinical trialsChapters00:00 – 01:06 – Introduction01:06 – 06:51 – Proteomics in pre-clinical studies06:51 – 11:40 – The importance of choosing the right model for preclinical work11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials17:10 – 19:29 – Proteomics tools in patient selection19:29 – 24:33 – Useful information that we get from proteomics that we can't get from genomics or transcriptomics24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy28:14 – 29:19 - Understanding why clinical trials fail29:19 – End - Outro ResourcesThe National Cancer Institute's webpage covering how clinical trials workPreprint on the miBrain model - An example of a new in vitro brain modelGeary et al., 2021 - Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical TrialsWasko et al., 2024 - Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerThe NCI-MATCH trail: Lessons for precision oncology – Report on a large-scale trial using genomic biomarkers to match cancer patients to treatmentsTumour-selective activity of RAS-GTP inhibition in pancreatic cancer – Study using proteomics to understand mechanisms of resistance to a cancer drug

Welcome to the Youtini Canon Book Club! In this episode, Emmi, Hannah, and JG break down their thoughts on The High Republic: Tempest Breaker by Cavan Scott, the Phase III audio drama. We get into our changing feelings on Lourna Dee, the endurance of Lourna and Quin's relationship, and the threats that still lie in wait for the Jedi and the Republic. Pour yourself a cup of caf and enjoy!

Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin reflects on the legacy of Temple. Temple, who is retiring, crafted the modern clinical trial paradigm, created the accelerated approval pathway, and set precedents for incorporating patient perspectives in regulatory decisions. Usdin also discusses the opportunities and threats for the agency under Trump 2.0.BioCentury's editors also discuss China's academic innovation, arguing that a wave of new target biology is now coming from Chinese university labs and the underwhelming results from CagriSema's latest readout. Phase III data for the most important weight loss candidate from  Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) failed to differentiate the product from Eli Lilly's Zepbound.View full story:https://www.biocentury.com/article/654574/temple-s-fda-legacy-plus-chinese-innovation-novo-obesity-data-a-biocentury-podcast00:00 - Introduction02:03 - Bob Temple's Legacy16:13 - China's Academic Innovation26:20 - CagriSema Obesity DataTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Featuring an interview with Dr Seth Wander, including the following topics: Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00) EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50) Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43) CME information and select publications

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase III CheckMate 77T study. Perioperative therapy has improved outcomes in patients with resectable NSCLC and is emerging as best practice but there is nuance to the delivery of this therapy. Guest: Dr. Tina Cascone is a Physician-Scientist and Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas and lead author of the CheckMate 77T manuscript in the New England Journal of Medicine Guest: Dr. Shun Lu is the Chief of Shanghai Lung Cancer Center and Shanghai Chest Hospital and Professor at Shanghai Jiaotong University. He is an executive board member of the Chinese Society of Clinical Oncology and past chair of Chinese Lung Cancer Association

[SEGMENT 2-1] Great Days for America 1 All the people behind the targeting of Trump will exposed in the coming weeks. They will all either accept pleas or be made to face justice. We have 4 years to correct the horrible wrongs faced by this great nation during the era of Biden, and era of politics replete with corruption and debauchery. Time made President Trump: Man of the Year. Not that he needed their endorsement.  [SEGMENT 2-2] Great Days for America 2 Trump went from pariah to GOAT. He's a HERO He went from quicksand under his feet to a firm foundation I don't know many presidents who go into office with this type of mandate, and I don't mean what we've conjured up in our minds as MAGA. Americans are overjoyed about Trump's return.   First president to ring the bell at the NYSE since 1985 when they chose Reagan. Trump's name will last as long as Reagan's in the lexicon of political discussions and particularly admiration by Conservatives.   The resignation of Christopher Wray is a great day for America as it will end the Weaponization of what has become known as the United States Department of Injustice. I just don't know what happened to him. We will now restore the Rule of Law for all Americans. Under the leadership of Christopher Wray, the FBI illegally raided my home, without cause, worked diligently on illegally impeaching and indicting me, and has done everything else to interfere with the success and future of America. They have used their vast powers to threaten and destroy many innocent Americans, some of which will never be able to recover from what has been done to them. Kash Patel is the most qualified Nominee to lead the FBI in the Agency's History, and is committed to helping ensure that Law, Order, and Justice will be brought back to our Country again, and soon. As everyone knows, I have great respect for the rank-and-file of the FBI, and they have great respect for me. They want to see these changes every bit as much as I do but, more importantly, the American People are demanding a strong, but fair, System of Justice. We want our FBI back, and that will now happen. I look forward to Kash Patel's confirmation, so that the process of Making the FBI Great Again can begin. Thank you   There is ONE reason why Fani Willis refuses to turn over her communications on J6. She's guilty and so are they. She has been INSTRUCTED not to turn this information over.  [SEGMENT 2-3] Great Days are Coming 3 – Pardons   Chris Wray's legacy will be turning the world's most powerful law enforcement agency into a domestic terror operation that includes raiding the home of the former president, entrapping individuals into politically-oriented hoaxes like Whitmer fednapping, colluding with Big Tech to protect the Biden crime family by censoring Americans, and using the FBI counterterrorism task force to investigate, raid, and arrest nearly 1,600 Americans who protested the 2020 election on January 6. His failures include record crime, a bleeding southern border, out of control fentanyl crisis, and historic low trust in the FBI. Seems impossible but the worst FBI director in US history. The damage he caused this country may never be fully repaired. WTF?! Joe Biden just pardoned multiple Chinese spies and an individual convicted of possessing child p*rnography   https://www.ft.com/content/3378545d-d1bc-4fe6-880c-69ff5c649a05 Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here. https://www.ft.com/content/3378545d-d1bc-4fe6-880c-69ff5c649a05China has hailed the release by the US of three Chinese citizens including an allegedly politically connected former student convicted of possessing child pornography. Jin Shanlin was freed as part of a rare prisoner swap negotiated with the Biden administration that China's foreign ministry said on Thursday was the result of “tireless” government efforts. While the other two Chinese citizens were imprisoned in the US on espionage-related convictions, Jin pleaded guilty in 2021 to possessing child pornography. During his trial in Texas, an FBI special agent testified that his family was “connected to influential members of the Communist party in China”, according to court records. China's foreign ministry said on Thursday its three citizens had been wrongfully detained by the US and were safely returned home through the “tireless efforts of the Chinese government”.  “This once again demonstrates that China will never abandon its compatriots under any circumstances, and the motherland will always be their strong support,” said foreign ministry spokesperson Mao Ning.  Jin, 26, had admitted possessing and distributing “more than 600 images and videos of child pornography” while he was studying for a PhD at Southern Methodist University in Texas.  Local police department investigators said an internet protocol address linked to Jin's residence had used a peer-to-peer network to share a video of “sexual assault of an infant by an adult male” along with other child porn.  Police said they found child pornography open on Jin's computer when they entered his home, which included “videos involving infants and toddlers”.     https://deepnewz.com/china/biden-grants-clemency-to-chinese-national-convicted-child-pornography-espionage-4efaf070 I asked for a comedic take on Biden's massive pardon spree, and particularly on this article where he pardoned Chinese nationals. [START] https://deepnewz.com/china/biden-grants-clemency-to-chinese-national-convicted-child-pornography-espionage-4efaf070 President Joe Biden has granted clemency to Shanlin Jin, a Chinese national convicted of possessing 47,000 images of child pornography. Yanjun Xu, a Chinese spy sentenced to 20 years for espionage. Jin had served four years of his 97-month sentence after pleading guilty. The Plano police confirmed 1,338 images and videos on Jin's computer, including infant sexual assault. For additional context, here is another article that references the deal: https://www.ft.com/content/3378545d-d1bc-4fe6-880c-69ff5c649a05 Was HUNTER on there? Xu was convicted for plotting to steal proprietary information from aviation companies, including GE Aviation. The decision to grant clemency to these individuals has sparked significant controversy and criticism. [END] The only people discussing this are Conservatives. Interestingly, if you Google "Biden pardons", the information on the pardon of the Chinese won't come up. You must dig really deep or go to X to find the link mentioned above. It's as if the fake news media doesn't want to report about the pardon of the Chinese nationals. Instead of highlighting these pardons, all the other stories highlight Americans who have turned their lives around, and now act as exemplary citizens. Even if you add "Chinese Pardons" to the Google search, no story reveals the pardons to the Chinese. I proposed that Biden pardoned these people at the behest of the Chinese government, because the perpetrators are spies, and Biden was threatened by the Chinese for his potential dealings in China for which he pardoned Hunter in Phase I of his pardons. Phase II is a Pardon-a-Palooza as Biden pardoned over 1,500 people under the guise that they were either sentenced too long for their crimes or other so-called humanitarian reasons. I'm not buying this, at least not for the Chinese pardons. Finally, Phase III is where Biden will go hog wild, as we say in the country. Phases I and II were all to set up what Biden is about to do. He's trying to spread the outrage, because Phase III will be huge, as Biden pardons his remaining family members, and all of the upper echelon of the agencies in the DOJ down to middle-management.    “Joe's Great Pardon Bazaar: Everything Must Go!”“Biden's Backroom Deals: Now with Free Spy Exchanges!”“The Art of the Pardon: Joe Biden Edition”“Pardon Me? The Biden Family Clearance Sale”“From Hard Drives to Hard Time: Biden's Clemency Chronicles”“Keeping Up with the Clemencies”. And the latest episode? Pardon-a-Palooza. Apparently, Joe's handing out pardons like Oprah hands out cars. “You get a pardon! You get a pardon! Everybody gets a pardon!” So, Joe Biden's pardoning spree is in full swing. And it's not like he's just handing out Get Out of Jail Free cards to someone who shoplifted a Snickers. No, we're talking about hardcore criminals. Chinese nationals convicted of espionage and, uh, crimes so heinous that even Jeffrey Epstein would've been like, “Whoa, too far.” A pretty low bar for clemency, eh? “Are you a threat to national security or basic human decency? Congratulations! You qualify!”   Let's Become a supporter of this podcast: https://www.spreaker.com/podcast/the-kevin-jackson-show--2896352/support.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.J&J and Legend have released new Phase III data for their drug Carvykti, showing nearly 90% of patients had no detectable cancer cells after treatment. This data could help them fend off competition from emerging CAR T therapies like Gilead and Arcellx's Anito-cel. Biontech also has promising breast cancer data for their drug BNT327, while Moderna's RSV vaccines are facing safety concerns. Meanwhile, there is pushback against IRA's controversial 'pill penalty'. Opportunities to become a US Pharmacopeia expert volunteer are available. In the biotech industry, Acelyrin terminated its drug Izokibep after failed Phase IIB/III data, Cellectar downsized by 60%, and M&A spending has been small this year.Pharma dealmaking in 2024 has mostly stayed under $5 billion, with the exception of Novo Holdings' acquisition of Catalent for $16.5 billion. The proposed EPIC Act, which aims to give small molecule drugs the same protection against price negotiation as biologics, faces challenges due to concerns over balancing the federal budget. The biotech IPO class of 2024 has struggled, with many companies tumbling from their original offer price after going public. Novo and Catalent's deal has received EU approval, Lilly is investing $3 billion in a Wisconsin site, and GSK is making agreements to further their presence in neurology. Carisma Therapeutics is cutting staff and reprioritizing their pipeline, while Relmada is exploring strategic alternatives after a failed asset in depression. Cellectar is downsizing by 60% as they explore options for their cancer drug.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Exkivity have raised concerns about the risks of this pathway. Despite some high-profile failures, the program has a strong track record, with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like Sarepta's Elevidys have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next.AbbVie's Tavapadon showed improvement in motor and daily living complications in a Phase III trial, following the failure of another key cerevel asset, Emraclidine. Relmada Therapeutics is considering strategic alternatives, including a potential sale, after halting two Phase III trials for a major depressive disorder drug. Other news includes BioAge discontinuing a Phase II obesity study, Merck's promising anti-ROR1 ADC data for lymphoma treatment, and Novo and Catalent's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies, while evidence grows for the potential of GLP-1s in Alzheimer's disease.Recent studies have shown that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may have potential in treating Alzheimer's disease. Phase III results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP-1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lilly over Novo in a head-to-head study, FDA action alerts, and promising cancer therapies from companies like AstraZeneca and Merus. The FDA is also investigating the safety of Bluebird's gene therapy Skysona for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP-1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.

This week, Jonathan is joined by Ed Smith, Professor at the University of Manchester, UK, to discuss proton beam therapy and radiation oncology.  Timestamps:     (00:00)-Introduction    (01:43)-Ed's favourite books and hiking spots   (05:32)-The rise of proton beam therapy (PBT)  (15:58)-PBT in the UK versus USA  (18:30)-TORPEdO: the UK's first Phase III clinical trial in PBT 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Trump has chosen Jay Bhattacharya from Stanford as the new head of the National Institutes of Health, adding to his controversial cabinet picks. Meanwhile, Eli Lilly is currently the best performing pharmaceutical stock of 2024. The newsletter will be taking a break for Thanksgiving and will return on December 2nd with more biopharma news. In other news, PTC has discontinued an ALS asset after a mid-stage failure, BridgeBio's ATTR-CM drug has been approved, Cassava's Alzheimer's drug has failed in Phase III, and Amgen's Maritide did not impress investors. Eli Lilly has seen a significant improvement in its share price this year, while other pharmaceutical companies have not been as fortunate. Additionally, there have been layoffs at Novartis, Recursion, and Kronos. Legal challenges over Lilly's GLP-1 shortages and Sarepta's investment in Arrowhead for RNA drugs are also highlighted.Eli Lilly leads the list of the biggest share movers in the pharmaceutical industry this year, with a significant improvement in its share price. However, other companies like Amgen have faced disappointments, with their weight loss drug Maritide falling short of investor expectations. Sage Therapeutics also suffered setbacks with the discontinuation of its lead candidate Dalzanemdor after clinical failures. Legal challenges over Lilly's GLP-1 shortages have highlighted the FDA's vulnerability post-Chevron deference. In other news, Roche acquires Poseida, Sarepta aims to diversify its pipeline with RNA drugs, and Trump's cabinet picks raise uncertainty in the biopharma environment. Novartis CEO promises more deals, while companies like Novartis, Recursion, and Kronos have announced layoffs. Subscribe for more relevant updates from BioSpace.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 22 November 2024. In this episode: Novo's semaglutide looks good in NASH; J&J's psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024. https://insights.citeline.com/scrip/podcasts/quick-listen-scrips-five-must-know-things-YDQU2ROM3JAXDD72TMXMOYZGGE/ Link to APAC Clinical Trials White Paper: https://www.citeline.com/en/resources/exploring-the-asia-pacific-clinical-trials-landscape Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Jedi Keeve Trennis and her allies defend themselves from one of Boolan's Children of the Storm in issues 7 and 8 of Cavan Scott's The High Republic from Marvel.   In this fully armed and operational episode of Podcast Stardust, we discuss: What happened in the prior two issues of The High Republic to get to this point, The Yacombe species and what their powers are, Lourna Dee and where she stands with the Jedi and the Nihil, The stress this conflict is placing on the Jedi and how we have seen this before, The death of a Jedi, The powers of the Children of the Storm, Jedi Master Sskeer and how he is handling Magrak syndrome, and more.   FInd our discussion of issues five and six in episode 756.   Thanks for joining us for another episode! Subscribe to Podcast Stardust for all your Star Wars news, reviews, and discussion wherever you get your podcasts. And please leave us a five star review on Apple Podcasts.   Find Jay and her cosplay adventures on J.Snips Cosplay on Instagram.   Join us for real time discussion on the RetroZap Discord Server here: RetroZap Discord. Follow us on social media: Twitter | Facebook | Instagram | Pinterest | YouTube. T-shirts, hoodies, stickers, masks, and posters are available on TeePublic. Find all episodes on RetroZap.com.

Jedi Keeve Trennis and her allies defend themselves from one of Boolan's Children of the Storm in issues 7 and 8 of Cavan Scott's The High Republic from Marvel.

In Episode 125, hosts Alyce and Laura are* old and amazing and celebrating everything Star Wars, which is also old and amazing! - We shall henceforth tackle all arguments and confrontations with the energy and attitude of a toddler- Star Wars movie drama continues with the most recent writer's exit (Variety via Puck News)- There's a new trailer for Skeleton Crew aka Skelly Crü, with an accompanying article on starwars.com- New images from Skeleton Crew from Empire Magazine (via Reddit)- Will Skelly Crü have ties to the 2019 novel, Star Wars: Force Collector? Alyce has a theory- December 3, 2024 is going to be a big day for Star Wars fans, as it marks the premiere of Skeleton Crew and the debut of The High Republic audio original, Tempest Breaker- Imagine Rancho Obi-Wan, but four times bigger? A new Star Wars memorabilia museum may be in the works- Star Wars is putting the “Knight” in Jedi Knight in a very literal way and it is amazing. Check out the new THR concept art and all the other publishing reveals from NYCC!- As it turns out, The Book of Boba Fett really did take inspiration from Parks & Rec- Recap on Tap is a non-spoiler review of The High Republic YA novel, Tears of the Nameless! We discuss some general plot points, characters and share our thoughts on the novel and Phase III so far. No spoilers, but if you want to avoid this discussion, skip 55:00 - 01:08:20.Helpful links referenced in this episode:- On the Oct 25 episode of The Jedi Way, Laura and Rocha talked about Rey movie writing shakeups, publishing reveals out of NYCC reveals and why Laura believes Gray Jedi is a stupid conceptTwitter: @forcetoastpod | @sLeiaAllDay | @ShutUp_LauraInstagram: @forcetoastpodEmail: forcetoastpod@gmail.comWebsite: forcetoastpod.com*This podcast contains a sh!t ton of profanity and boozin. You can find a bleeped version of this podcast absolutely nowhere. Cheers!